Tvardi Therapeutics (TVRD) has an average rating of overweight and mean price target of $8.17, according to analysts polled by FactSet.
What else is happening in Research?
Research
BofA Securities Initiates Coverage on SPX Technologies With Buy Rating, $235 Price Target
SpaceX (SPCX) has an average rating of overweight and mean price target of $220.81, according to analysts polled by FactSet.Price: $219.24, Change: $-12.95, Percent Change: -5.58%
$SPXC
Research
Wells Fargo Upgrades MGM Resorts International to Equalweight From Underweight, Price Target is $48.30
MGM Resorts International (MGM) has an average rating of overweight and mean price target of $48.91, according to analysts polled by FactSet.Price: $46.81, Change: $-0.07, Percent Change: -0.15%
$MGM
Research
LifeSci Capital Downgrades Crinetics Pharmaceuticals to Market Perform From Outperform, Price Target is $85
Crinetics Pharmaceuticals Inc (CRNX) has an average rating of overweight and mean price target of $83.18, according to analysts polled by FactSet.
$CRNX